ClinicalTrials.Veeva

Menu
C

Children's Hospital Colorado | Pediatric Infectious Disease

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ubrogepant
Ozanimod
Mavacamten
Trofinetide
Ribavirin
Ruxolitinib
Repotrectinib
Ombitasvir
ABT-414
Dalbavancin

Parent organization

This site is a part of Children's Hospital Colorado

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 42 total trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lympho...

Active, not recruiting
Leukemia
Drug: Methotrexate
Drug: Thioguanine

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or me...

Enrolling
Locally Advanced Solid Tumors
Primary CNS Tumors
Drug: Oral repotrectinib (TPX-0005)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Placebo
Drug: Mavacamten

The purpose of this study is to evaluate the efficacy, safety, drug levels, and drug effects of ozanimod in pediatric participants with moderately to...

Active, not recruiting
Crohn Disease
Drug: Ozanimod

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, rec...

Active, not recruiting
Desmoplastic Small Round Cell Tumor
Drug: Ramucirumab
Drug: Cyclophosphamide

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Upadacitinib

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous...

Active, not recruiting
Mitochondrial Myopathies
Mitochondrial DNA Mutation
Drug: Elamipretide
Drug: Placebo

The aim of this study is to compare the outcomes, ease of use, and cost of the Werewolf FLOW50 device to the institutional standard of care which is...

Enrolling
Anterior Cruciate Ligament Injuries
Arthrofibrosis of Knee
Device: Werewolf FLOW 50
Other: Control

Trial sponsors

AbbVie logo
University of Colorado Denver (CU Denver) logo
Bristol-Myers Squibb (BMS) logo
Children's Hospital Colorado logo
Sobi logo
Acadia Pharmaceuticals logo
Allergan logo
Boston Children's Hospital logo
Children's Hospital of Philadelphia (CHOP) logo
Cincinnati Children's Hospital Medical Center logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems